[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"leadSponsorName\":\"I.M. Sechenov First Moscow State Medical University\",\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:":494},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,17,0,[8,47,80,108,138,172,201,226,252,281,307,335,357,383,410,439,467],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":18,"targetDuration":4,"studyType":21,"phases":22,"briefSummary":24,"conditions":25,"keywords":28,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":35,"lastUpdatePostDateStruct":36,"startDateStruct":39,"completionDateStruct":41,"leadSponsor":43,"locationsCount":46},"100645298","etiologic-diagnosis-algorithm-in-infective-endocarditis-100645298",false,"NCT07682389","Etiologic Diagnosis Algorithm in Infective Endocarditis","Development and Validation of An Algorithm of Etiological Diagnosis of Infective Endocarditis in Adults: An Open-Label Multicenter Randomized Clinical Trial","Inclusion Criteria:\n\n* Informed consent,\n* Age ≥ 18,\n* IE (definite or possible per the 2023 Duke-International Society for Cardiovascular Infectious Diseases Criteria for Infective Endocarditis)\n\nExclusion Criteria:\n\n* Pregnancy\u002Fbreastfeeding\n* Unconfirmed or rejected IE diagnosis,\n* Very high risk of death within 14 days due to severe complications of the main or concomitant disease(s), according to the physician's opinion;\n* Prior use of antibiotic therapy (except documented treatment failure).","ALL","18 Years",{"count":19,"type":20},128,"ESTIMATED","INTERVENTIONAL",[23],"NA","The goal of this study is to evaluate the impact of a diagnostic algorithm combining culture-based and molecular methods on the frequency of etiotropic antibiotic therapy prescription within 14 days of diagnosis of infective endocarditis",[26,27],"Infective Endocarditis","Microbiology",[29,30,31,32,33],"Infective endocarditis","PCR","Antibiotic therapy","Etiological diagnosis","Sequencing","RECRUITING","2026-06-28",{"date":37,"type":38},"2026-07-02","ACTUAL",{"date":40,"type":38},"2026-01-20",{"date":42,"type":20},"2027-02-20",{"name":44,"class":45},"I.M. Sechenov First Moscow State Medical University","OTHER",3,{"id":48,"slug":49,"hasResults":11,"nctId":50,"briefTitle":51,"officialTitle":52,"acronym":4,"eligibilityCriteria":53,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":54,"targetDuration":4,"studyType":56,"phases":4,"briefSummary":57,"conditions":58,"keywords":63,"overallStatus":70,"whyStopped":4,"lastUpdateSubmitDate":71,"lastUpdatePostDateStruct":72,"startDateStruct":74,"completionDateStruct":76,"leadSponsor":78,"locationsCount":79},"100638027","ai-enhanced-single-lead-ecg-screening-for-coronary-stenosis-100638027","NCT07579624","AI-Enhanced Single-Lead ECG Screening for Coronary Stenosis","Screening for Significant Coronary Artery Stenosis Using Single-channel Electrocardiogram Analysis With Artificial Intelligence Elements","Inclusion Criteria:\n\n* Presence of written informed consent from the patient to participate in the study.\n* Age 18 years and older.\n* Outpatient visit and\u002For hospitalization at the research center with coronary visualization performed.\n\nNon-inclusion criteria:\n\n* Absence of sufficient data on coronary anatomy and stenosis significance.\n* Any conditions impairing the quality of single-channel ECG recording (Parkinson's disease, essential tremor, and others).\n* Absence of written informed consent from the patient to participate in the study.\n\nExclusion Criteria:\n\n* Patient's unwillingness to continue participation in the study.\n* Inability to perform full analysis of single-channel ECG digital characteristics.\n* Refusal of coronary visualization methods for any reason.",{"count":55,"type":20},400,"OBSERVATIONAL","It is a prospective, controlled, single-center, non-randomized, observational study. Two patient groups are planned for inclusion: the first - 200 patients with significant coronary artery stenosis confirmed by coronary angiography (CAG) or multislice computed tomography (MSCT) results; the second - a control group consisting of 200 patients without significant stenosis according to CAG or MSCT data.\n\nAll study subjects will have a date of coronary artery imaging via CAG or MSCT with assessment of myocardial perfusion.\n\nStress echocardiography tests or fractional flow reserve (FFR) assessment will be conducted as indicated.\n\nAll patients included in the study will undergo ECG recording within 1 month before or after CAG or MSCT in standard lead I for 1 minute, followed by spectral analysis of the obtained data, which will be stored at the remote monitoring center of Sechenov University without being linked to the personal data of patients. A spectral analysis of the electrocardiogram will be performed using a continuous wavelet transform.\n\nThe result of this study will be the identification of ECG parameters that correlate with significant coronary artery stenosis.",[59,60,61,62],"Ischemic Heart Disease","Coronary Artery Stenosis","Stable Angina Pectoris","Acute Coronary Syndromes",[64,59,65,66,67,68,69],"coronary","Single-Channel ECG","Artificial Intelligence","AI-Enhanced Screening","Non-Invasive Diagnostics","Angina","NOT_YET_RECRUITING","2026-05-06",{"date":73,"type":38},"2026-05-12",{"date":75,"type":20},"2026-05-01",{"date":77,"type":20},"2027-12-01",{"name":44,"class":45},1,{"id":81,"slug":82,"hasResults":11,"nctId":83,"briefTitle":84,"officialTitle":85,"acronym":4,"eligibilityCriteria":86,"healthyVolunteers":87,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":88,"targetDuration":4,"studyType":56,"phases":4,"briefSummary":90,"conditions":91,"keywords":95,"overallStatus":70,"whyStopped":4,"lastUpdateSubmitDate":102,"lastUpdatePostDateStruct":103,"startDateStruct":104,"completionDateStruct":105,"leadSponsor":107,"locationsCount":79},"100624652","screening-for-pulmonary-embolism-using-single-channel-electrocardiogram-100624652","NCT07412418","Screening for Pulmonary Embolism Using Single-channel Electrocardiogram","Screening for Pulmonary Embolism Using Single-channel Electrocardiogram Data Using Machine Learning Models","Inclusion Criteria:\n\n1. A clinical condition requiring exclusion of acute pulmonary embolism;\n2. The presence of written informed consent of the patient to participate in the study;\n3. Age from 18 years old and older\n\nNon-inclusion criteria:\n\n1. Refusal to undergo examination or the inability to reliably verify or exclude the diagnosis of pulmonary embolism;\n2. Treatment, in particular anticoagulant therapy, before recording a single-lead ECG;\n3. Conditions in which recording an ECG in lead I is not possible (congenital anomalies of the upper limbs, traumatic amputation of the upper limbs, tremor, etc.);\n4. Refusal to sign written informed consent to participate in the study.\n\nExclusion Criteria:\n\n1. Poor ECG quality, preventing the necessary analysis of a single-channel ECG;\n2. Incomplete examination, preventing a reliable determination of the presence or absence of pulmonary embolism;\n3. Refusal to further participate in the study.",true,{"count":89,"type":20},500,"It is a prospective, controlled, single-center, observational, non-randomized study. The study is planned to include at least 500 patients 18 years old and older (300 patients in the training sample and 200 patients in the test sample.\n\nThe study will include all patients requiring exclusion of the diagnosis of acute pulmonary embolism. Patients will be examined according to clinical guidelines to confirm the diagnosis of pulmonary embolism (laboratory, clinical and instrumental).\n\nDuring the course of the study, the authors of the work do not interfere with the scope of the examination, which is caried out on patients in accordance with clinical guidelines.\n\nAll patients included in the study will undergo electrocardiogramm (ECG) in standart lead I for 1 minute, followed by spectral analysis of the obtained data, which will be stored at the Remote monitoring center of Sechenov University without being linked to the personal data of patients. A spectral analysis of the electrocardiogram will be performed using a continuous wavelet transformation. The result of this study will be the identification of ECG parameters that will correlate with pulmonary embolism.",[92,93,94],"Pulmonary Embolism (Diagnosis)","Respiratory Failure With Hypoxia","Chronic Obstructive Pulmonary Disease (COPD)",[96,97,98,99,100,101],"Screening","single-channel electrocardiogram","machine learning models","pulmonary embolism","respiratory failure","chronic obstructive pulmonary disease","2026-04-30",{"date":75,"type":38},{"date":75,"type":20},{"date":106,"type":20},"2028-07-30",{"name":44,"class":45},{"id":109,"slug":110,"hasResults":11,"nctId":111,"briefTitle":112,"officialTitle":113,"acronym":114,"eligibilityCriteria":115,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":116,"targetDuration":118,"studyType":56,"phases":4,"briefSummary":119,"conditions":120,"keywords":122,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":130,"lastUpdatePostDateStruct":131,"startDateStruct":133,"completionDateStruct":135,"leadSponsor":137,"locationsCount":79},"100635396","patient-reported-health-status-assessment-using-the-kccq-for-early-detection-of-heart-failure-worsening-100635396","NCT07552142","Patient-Reported Health Status Assessment Using the KCCQ for Early Detection of Heart Failure Worsening","Patient-Reported Health Status Assessment Using the Kansas City Cardiomyopathy Questionnaire for Early Detection of Heart Failure Worsening","KCCQ-WHF","Inclusion Criteria:\n\n* Established diagnosis of chronic HF with reduced, mildly reduced, or preserved ejection fraction, NYHA II-III\n* History of heart failure (HF) hospitalization within the last 6 months before enrollment, defined as the presence of dyspnea, elevated NT-proBNP ≥300 pg\u002FmL (sinus rhythm) or ≥600 pg\u002FmL (if AF), and 2 of the following: i. Rales on chest auscultation or signs of congestion on X-ray\u002FCT scan; ii. Peripheral Oedema; iii. Loop diuretics IV at admission\n* Free of signs and symptoms of congestion, defined as JVP of \\\u003C8 cm, with no orthopnea, pulmonary rales, and with trace peripheral edema or no edema.\n* Stable doses of oral loop diuretics, if prescribed\n* Ability to provide informed consent\n\nExclusion Criteria:\n\n* Acute coronary syndrome, cardiac surgery, pulmonary embolism, cerebrovascular accident, ablation of atrial flutter\u002Ffibrillation, valve repair\u002Freplacement, implanted cardioverter defibrillator or urgent PCI within the last 3 months\n* Planned interventions, including major cardiac surgery (coronary artery bypass grafting, valve repair\u002Freplacement, ventricular assist device, cardiac transplantation), coronary revascularization, implantation of a cardiac device or ablation of atrial flutter\u002Ffibrillation during the study\n* Previous cardiac transplantation and candidates for heart transplantation\n* Complex congenital heart disease\n* Heart failure due to active myocarditis, pericardial constriction, known hypertrophic cardiomyopathy or cardiac amyloidosis, or uncorrected severe valvular heart disease\n* Primary pulmonary hypertension, chronic pulmonary embolism, severe pulmonary disease\n* Cirrhosis, chronic active hepatitis, or other severe hepatic disease\n* Significant drug or alcohol abuse during the last year\n* Hemodialysis\n* Infective endocarditis\n* Any active cancer",{"count":117,"type":20},120,"12 Months","This observational feasibility study aims to assess (i) how practical and acceptable repeated KCCQ assessments are; (ii) the connection between changes over time in KCCQ scores and signs of congestion; and (iii) clinical outcomes, including worsening heart failure events or cardiovascular death (CVD), and the time between 5- and 10-point KCCQ changes and clinical events.",[121],"Heart Failure",[123,124,125,126,127,128,129],"Kansas City Cardiomyopathy Questionnaire","Heart failure","worsening heart failure","monitoring","Cardiovascular Diseases","Heart Diseases","Congestion","2026-04-20",{"date":132,"type":38},"2026-04-27",{"date":134,"type":38},"2025-10-01",{"date":136,"type":20},"2028-04-01",{"name":44,"class":45},{"id":139,"slug":140,"hasResults":11,"nctId":141,"briefTitle":142,"officialTitle":143,"acronym":4,"eligibilityCriteria":144,"healthyVolunteers":87,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":145,"targetDuration":4,"studyType":56,"phases":4,"briefSummary":147,"conditions":148,"keywords":156,"overallStatus":70,"whyStopped":4,"lastUpdateSubmitDate":164,"lastUpdatePostDateStruct":165,"startDateStruct":167,"completionDateStruct":169,"leadSponsor":171,"locationsCount":4},"100623450","screening-for-cardiac-and-cardiac-associated-pathology-using-single-channel-electrocardiogram-100623450","NCT07396792","Screening for Cardiac and Cardiac-associated Pathology Using Single-channel Electrocardiogram","Screening for Cardiac and Cardiac-associated Pathology Using Single-channel Electrocardiogram Analyzed With Machine Learning Models","Inclusion Criteria:\n\n1. The presence of written informed consent of the patient to participate in the study\n2. Availability of examination data allowing for the verification or exclusion of cardiac and cardiac-associated pathology\n3. Age 18 years old and older\n\nNon-inclusion criteria:\n\n1. Patients with an implanted permanent pacemaker;\n2. ECG changes that prevent spectral analysis;\n3. Conditions that may impair the quality of the ECG recording (Parkinson's disease, essential tremor, etc.);\n4. Conditions that make ECG recording in lead I impossible (congenital anomalies of the upper limbs, traumatic amputation of the upper limbs).\n5. Lack of written informed consent from the patient to participate in the study.\n\nExclusion Criteria:\n\n1. Poor quality of the ECG recording on a single-channel ECG monitor\n2. Insufficient examination data to verify or exclude cardiac or cardiac-associated pathology;\n3. Patient's unwillingness to continue participating in the study for any reason.",{"count":146,"type":20},4000,"It is a prospective, controlled, single-center, observational, non-randomized study. The study is planned to include at least 4000 patients 18 years old and older in the training sample and 1000 patients over 18 years old in the test sample (the total number of patients is at least 5000 people). Patients will be included in the study if they have undergone a full examination (laboratory, clinical and instrumental), allowing for the verification or exclusion of cardiac and cardiac-associated pathology in accordance with current recommendations. During the course of the study, the authors of the work do not interfere with the above-mentioned scope of the examination, which is carried out on patients in accordance with clinical guidelines. All patients included in the study will undergo ECG recording in standard lead I for 1 minute twice, followed by spectral analysis of the obtained data, which will be stored at the remote monitoring center of Sechenov University without being linked to the personal data of patients. A spectral analysis of the electrocardiogram will be performed using a continuous wavelet transform. The result of this study will be the identification of ECG parameters that will correlate with cardiac and cardiac-associated pathology",[149,150,151,121,152,153,154,155],"Arterial Hypertension","Heart Rhythm Disorders","Valvular Heart Diseases","Diabetes Mellitus","Chronic Kidney Disease (Stage 3-4)","Metabolic Syndrome","Coronary Artery Disease",[96,157,97,98,158,159,160,161,162,163],"Electrocardiogramm","Coronary artery disease","diabetes mellitus","metabolic syndrome","anemia","hypercholesterolemia","arterial hypertension","2026-04-13",{"date":166,"type":38},"2026-04-16",{"date":168,"type":20},"2026-04-01",{"date":170,"type":20},"2028-05-13",{"name":44,"class":45},{"id":173,"slug":174,"hasResults":11,"nctId":175,"briefTitle":176,"officialTitle":177,"acronym":4,"eligibilityCriteria":178,"healthyVolunteers":11,"sex":179,"minAge":17,"maxAge":180,"enrollmentInfo":181,"targetDuration":4,"studyType":21,"phases":183,"briefSummary":184,"conditions":185,"keywords":187,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":193,"lastUpdatePostDateStruct":194,"startDateStruct":196,"completionDateStruct":198,"leadSponsor":200,"locationsCount":79},"100632812","maternal-and-fetal-electrocardiograms-separation-algorithm-100632812","NCT07518550","Maternal and Fetal Electrocardiograms Separation Algorithm","The Development and Validation of Maternal and Fetal Electrocardiograms (ECG) Separation Algorithm Based on Artificial Intelligence Application","Inclusion Criteria:\n\n* Age over 18 years\n* Recordings obtained during the second or third trimester of pregnancy\n* Recording duration of at least 5 minutes\n* Singleton pregnancy\n* Signed informed consent\n\nExclusion Criteria:\n\n* Age under 18 years;\n* Multiple pregnancy;\n* Recent medical procedures or interventions that could affect the quality of electrocardiographic data;\n* Severe maternal conditions (e.g., severe eclampsia, shock, severe organ failure, etc.);\n* Severe fetal conditions (e.g., significant hypoxia, severe placental-fetal syndrome, and other life-threatening states).\n\nExclusion criteria:\n\n1\\. Patient's refusal to continue participation in the study.","FEMALE","55 Years",{"count":182,"type":20},350,[23],"Effective monitoring of fetal heart activity during the second and third trimesters remains a vital challenge in perinatal medicine. This study proposes an adaptive algorithm for extracting the fetal electrocardiograms signal from abdominal ECG in pregnant women, considering the physiological characteristics of each trimester. Utilizing modern machine learning methods, independent component analysis, and data from wearable textile electrodes. The goal is to enhance the accuracy and reliability of automatic signal separation. A dataset of 300 recordings will be collected and analyzed. The resulting algorithm will enable rapid and precise detection of fetal heartbeats. To validate the algorithm, 50 patients will be recruited separately.",[186],"Pregnancy Related",[188,189,190,191,192],"pregnancy","maternal and fetal electrocardiograms separation","2-3 trimester","abdominal ECG signals","artificial intelligence","2026-04-02",{"date":195,"type":38},"2026-04-08",{"date":197,"type":38},"2026-02-12",{"date":199,"type":20},"2028-05-30",{"name":44,"class":45},{"id":202,"slug":203,"hasResults":11,"nctId":204,"briefTitle":205,"officialTitle":205,"acronym":206,"eligibilityCriteria":207,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":208,"targetDuration":4,"studyType":21,"phases":210,"briefSummary":211,"conditions":212,"keywords":215,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":218,"lastUpdatePostDateStruct":219,"startDateStruct":221,"completionDateStruct":223,"leadSponsor":225,"locationsCount":79},"100628733","total-knee-arthroplasty-in-varus-deformity-100628733","NCT07465484","Total Knee Arthroplasty in Varus Deformity","TKA in varus","Inclusion Criteria:\n\n1. Patients over 18 years of age with grade 3-4 knee osteoarthritis (according to Kellgren-Lawrence) and pain score of 5 or higher on a 10-point VAS scale.\n2. Varus deformity of the lower limb (HKA angle \\\u003C177°, or varus \\>3°)\n3. Anesthesia risk according to the ASA scale of no more than III.\n4. BMI less than 35 kg\u002Fm2.\n5. Patient must be monitored throughout the entire study period (12 months).\n6. Patient must be mentally competent and compliant.\n7. Patient must provide written informed consent to participate in the study.\n\nExclusion Criteria:\n\n1. Body mass index \\> 40 kg\u002Fm².\n2. Instability of the collateral ligaments of the knee joint requiring the installation of ligamentous systems, presence of primary severe bone defects.\n3. Impaired weight-bearing ability of the contralateral limb.\n4. Presence of metal implants or foreign bodies in the lower extremities.\n5. Previous knee interventions, such as reconstruction of the knee ligament apparatus, or corrective osteotomies of the femur and tibia.\n6. Patient refusal to participate in the study.\n7. Patient failure to comply with the recommendations of the treating physician or the prescribed regimen.",{"count":209,"type":20},300,[23],"For the first time, a comparative analysis of the limb axis in patients with unilateral knee OA will be conducted compared to the contralateral uninjured side using Multisliced computed tomography (MSCT) and vertical CT (weight-bearing CT). This analysis will identify the pathological and physiological degrees of varus in patients with unilateral gonarthrosis. Indications for mechanical and kinematic limb axis alignment will be substantiated depending on the degree of varus deformity. Aim of the study: To improve the results of total knee arthroplasty in patients with varus deformity by optimizing the degree of varus correction. Objectives: To analyze physiological and pathological varus in patients with unilateral osteoarthritis under physiological loading. To develop an algorithm for applying various types of limb alignment.",[213,214],"Knee Osteoarthritis","Knee Osteoarthritis in Varus",[216,217],"Kinematic and Mechanical alignment","Weight-bearing CT","2026-03-06",{"date":220,"type":38},"2026-03-12",{"date":222,"type":38},"2024-09-01",{"date":224,"type":20},"2027-08-31",{"name":44,"class":45},{"id":227,"slug":228,"hasResults":11,"nctId":229,"briefTitle":230,"officialTitle":231,"acronym":4,"eligibilityCriteria":232,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":233,"targetDuration":4,"studyType":56,"phases":4,"briefSummary":234,"conditions":235,"keywords":240,"overallStatus":70,"whyStopped":4,"lastUpdateSubmitDate":245,"lastUpdatePostDateStruct":246,"startDateStruct":248,"completionDateStruct":249,"leadSponsor":251,"locationsCount":79},"100624655","guideline-adherence-in-dyslipidemia-with-clinical-decision-support-100624655","NCT07412457","Guideline Adherence in Dyslipidemia With Clinical Decision Support","Assessment of Adherence to Clinical Practice Guidelines in Patients With Dyslipidemia Using a Clinical Decision Support System","Inclusion Criteria:\n\n1. Availability of the required amount of patient data for completion of the questionnaire-based system;\n2. Age 18 years or older;\n3. Signed informed consent to participate in the study.\n\nNon-inclusion criteria:\n\n1. Patients with insufficient data to complete the questionnaire;\n2. Refusal to sign informed consent for participation in the study.\n\n   Exclusion Criteria:\n3. Absence of a consensus opinion on the clinical case among two of the three experts.",{"count":89,"type":20},"Objective: To validate the performance of the developed clinical decision support system (CDSS) for participants with lipid metabolism disorders based on a decision tree algorithm.\n\nMaterials and Methods: A clinical decision support system for participants with lipid profile abnormalities will be developed using the Orbeon open-source online form creation platform based on current clinical guidelines.\n\nDuring the CDSS pilot implementation, the electronic medical records (EMRs) of 500 participants from the Institute of Personalized Cardiology of the Biomedical Science and Technology Park at Sechenov University will be analyzed.\n\nRetrospective data on prescribed lipid-lowering therapy extracted from the EHR will be compared with the CDSS recommendations. The accuracy of the decisions will be assessed by three independent experts based on digitized clinical and laboratory patient profiles.\n\nThe primary endpoint of the study will be to determine the accuracy of the system.\n\nResults: This study will result in the development (creation) and pilot application of the CDSS program in participants with dyslipidemia in real clinical practice.\n\nConclusion: The developed CDSS system for dyslipidemia will significantly reduce the time required for clinical decision-making and help avoid errors in the interpretation of patient data.",[236,155,237,238,239],"Dyslipidemia","Atherosclerosis of Major Arteries","Cardiovascular Risk","Subclinical Atherosclerosis",[241,242,243,244],"dyslipidemia","atherosclerosis","revascularization","cardiovascular risk","2026-02-22",{"date":247,"type":38},"2026-02-24",{"date":168,"type":20},{"date":250,"type":20},"2027-09-30",{"name":44,"class":45},{"id":253,"slug":254,"hasResults":11,"nctId":255,"briefTitle":256,"officialTitle":257,"acronym":4,"eligibilityCriteria":258,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":259,"targetDuration":4,"studyType":56,"phases":4,"briefSummary":260,"conditions":261,"keywords":267,"overallStatus":70,"whyStopped":4,"lastUpdateSubmitDate":274,"lastUpdatePostDateStruct":275,"startDateStruct":277,"completionDateStruct":279,"leadSponsor":280,"locationsCount":4},"100619774","predicting-severe-cardiac-arrhythmias-in-the-perioperative-period-using-ai-ecg-100619774","NCT07348991","Predicting Severe Cardiac Arrhythmias in the Perioperative Period Using AI-ECG","Predicting Atrial Fibrillation and Life-threatening Cardiac Arrhythmias and Conduction Disorders in the Perioperative Period in High Cardiac Risk Surgery Using Artificial Intelligence Elements","Inclusion Criteria:\n\n* Patients over 18 years of age;\n* Scheduled surgery with high cardiac risk\n* Informed consent was given to participate in the study\n\nExclusion Criteria:\n\n* Cancellation of the surgery for any reason;\n* The patient's unwillingness to continue participating in the study;\n* Poor quality of the ECG recording on a single-channel ECG monitor.",{"count":209,"type":20},"During the preoperative examination, in addition to the standard examination recommended before high-risk cardiac surgeries, a digital single-lead ECG is recorded using portable CardioQUARK devices. This ECG is analyzed for time, amplitude, and frequency parameters-more than 200 parameters per cardiac cycle. Additionally, the available parameters of a standard 12-lead ECG recording are determined. All parameters of both single-lead and 12-lead ECGs will be included in a multivariate regression analysis to determine the optimal method for predicting atrial fibrillation, life-threatening cardiac arrhythmias, and conduction abnormalities in the perioperative period after high-risk cardiac procedures.\n\nThe study will include patients undergoing high-risk cardiac surgeries, such as those on the heart, aorta, esophagus, pancreas, liver, and lungs, as well as high-risk oncological surgeries. A partial analysis will also be performed depending on the type of intervention. Rhythm and conduction disturbances will be recorded during surgery, as well as in the postoperative period, using ECG monitors, 24-hour ECG monitoring, and repeated recordings of a standard ECG when complaints or signs of unstable hemodynamics arise",[262,263,264,265,266],"Atrial Fibrillation","Atrioventricular Block, Second and Third Degree","Sinus Node Dysfunction","Ventricular Tachycardia (VT)","Ventricular Fibrillation",[268,269,270,271,272,273],"Electrocardiogram","Artificial intelligence","Cardiac arrhythmias","Atrioventricular block","Perioperative","Atrial fibrillation","2026-02-09",{"date":276,"type":38},"2026-02-10",{"date":278,"type":20},"2026-12-31",{"date":199,"type":20},{"name":44,"class":45},{"id":282,"slug":283,"hasResults":11,"nctId":284,"briefTitle":285,"officialTitle":285,"acronym":4,"eligibilityCriteria":286,"healthyVolunteers":11,"sex":16,"minAge":287,"maxAge":288,"enrollmentInfo":289,"targetDuration":4,"studyType":56,"phases":4,"briefSummary":291,"conditions":292,"keywords":294,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":299,"lastUpdatePostDateStruct":300,"startDateStruct":302,"completionDateStruct":304,"leadSponsor":306,"locationsCount":79},"100614497","metabolomics-in-the-diagnosis-and-treatment-of-asthma-in-children-100614497","NCT07280364","Metabolomics in the Diagnosis and Treatment of Asthma in Children","Inclusion Criteria:\n\n* Age from 12 to 17 years old\n* Confirmed diagnosis of asthma\n* Informed voluntary consent to participate in the study\n\nExclusion Criteria:\n\n* age under 12 years\n* no established diagnosis of asthma\n* concomitant severe somatic, metabolic, and endocrine diseases\n* patient's withdrawal of informed consent","12 Years","17 Years",{"count":290,"type":20},100,"The goal of this observational study is to learn about the metabolomic profile of blood and urine in children 12-17 years with asthma. The main question it aims to answer is:\n\n• Are there metabolites in the blood and urine that are specific for asthma exacerbation? Participants already receive standard therapy as part of their regular medical care for asthma.",[293],"Asthma",[295,296,297,298],"bronchial asthma","children","metabolomics","metabolites","2026-01-27",{"date":301,"type":38},"2026-01-28",{"date":303,"type":38},"2024-03-13",{"date":305,"type":20},"2026-08",{"name":44,"class":45},{"id":308,"slug":309,"hasResults":11,"nctId":310,"briefTitle":311,"officialTitle":312,"acronym":4,"eligibilityCriteria":313,"healthyVolunteers":87,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":314,"targetDuration":4,"studyType":56,"phases":4,"briefSummary":315,"conditions":316,"keywords":319,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":327,"lastUpdatePostDateStruct":328,"startDateStruct":330,"completionDateStruct":332,"leadSponsor":334,"locationsCount":79},"100618336","breath-mass-spectrometry-in-metabolic-syndrome-and-metabolically-healthy-obesity-100618336","NCT07330297","Breath Mass Spectrometry in Metabolic Syndrome and Metabolically Healthy Obesity","The Capabilities of Exhaled Breath Mass Spectrometry in Identifying Metabolic Syndrome and Metabolically Healthy Obesity","Inclusion Criteria:\n\n* For Group 1 (Metabolic syndrome): Age \\>18 years, signed informed consent, diagnosis of Metabolic Syndrome (IDF 2006 criteria: waist circumference \\>94 cm (men)\u002F \\>80 cm (women) + ≥2 of: BP ≥130\u002F85 mmHg or antihypertensive therapy; TG ≥1.7 mmol\u002FL; HDL-C \\\u003C1.03 mmol\u002FL (men) \u002F \\\u003C1.29 mmol\u002FL (women); Fasting glucose ≥5.6 mmol\u002FL).\n* For Group 2 (Metabolically healthy obesity): Age \\>18 years, signed informed consent, waist circumference ≥94 cm (men) \u002F ≥80 cm (women), absence of other Metabolic Syndrome criteria (hypertension, dyslipidemia, impaired fasting glucose).\n* For Group 3 (Control): Age \\>18 years, signed informed consent, normal BMI, absence of signs of Metabolic Syndrome.\n\nNon-inclusion criteria for all groups:\n\n* Inability to provide informed consent;\n* History of myocardial infarction or stroke;\n* Chronic kidney disease stage 3B, 4, 5 (eGFR \\\u003C30 ml\u002Fmin\u002F1.73m2);\n* Acute or subacute cardiovascular disease;\n* Familial hypercholesterolemia;\n* Bronchopulmonary diseases;\n* Acute or chronic infectious diseases;\n* Type 1 or Type 2 diabetes mellitus;\n* Systemic connective tissue diseases;\n* Current or past history of oncological diseases;\n* Severe liver dysfunction, decompensated liver cirrhosis (Child-Pugh class C);\n* Pregnancy or lactation;\n* Severe mental illness (severe dementia, schizophrenia);\n* Comorbid conditions with life expectancy less than 1 year.\n\nExclusion Criteria:\n\n* Patient refusal to continue participation in the study;\n* Identification of any non-inclusion criteria after enrollment.",{"count":209,"type":20},"This study aims to develop a non-invasive diagnostic method for metabolic syndrome (MetS) and metabolically healthy obesity (MHO) through analysis of exhaled air. Using proton-transfer-reaction mass spectrometry combined with machine learning algorithms, we will characterize volatile organic compound profiles in 300 participants across three groups: MetS patients, MHO patients, and healthy controls. The primary goal is to create and validate a classification model capable of accurately differentiating these metabolic states based on breath analysis.",[154,317,318],"Obesity & Overweight","Metabolically Healthy Obesity",[320,321,322,66,323,324,325,326],"Breath Analysis","Volatile Organic Compounds","Proton-Transfer-Reaction Mass Spectrometry","Machine Learning","Metabolic syndrome","Obesity","Metabolically healthy obesity","2025-12-29",{"date":329,"type":38},"2026-01-09",{"date":331,"type":38},"2024-09-19",{"date":333,"type":20},"2026-12-30",{"name":44,"class":45},{"id":336,"slug":337,"hasResults":11,"nctId":338,"briefTitle":339,"officialTitle":340,"acronym":4,"eligibilityCriteria":341,"healthyVolunteers":87,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":342,"targetDuration":4,"studyType":56,"phases":4,"briefSummary":344,"conditions":345,"keywords":348,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":350,"lastUpdatePostDateStruct":351,"startDateStruct":353,"completionDateStruct":355,"leadSponsor":356,"locationsCount":79},"100600586","screening-of-valvular-heart-disease-using-single-channel-electrocardiogram-100600586","NCT07099417","Screening of Valvular Heart Disease Using Single-channel Electrocardiogram","Screening of Valvular Heart Disease Using Single-channel Electrocardiogram Analyzed With Machine Learning Models","Inclusion Criteria:\n\n* The presence of written informed consent of the patient to participate in the study\n* Age from 18 years\n* Outpatient treatment and \u002F or hospitalization in a research center\n\nExclusion Criteria:\n\n* Reluctance of the patient to participate in the study\n* Poor quality ECG recording on a single-channel ECG monitor\n* Poor visualization of the heart during echocardiographic study\n* Acute psychotic reactions that arose during research\n* An exacerbation of chronic diseases requiring treatment tactics for the patient and preventing his further participation in the study.\n\nNon-inclusion criteria:\n\n* Poor quality ECG recording on a single-channel ECG monitor\n* Conditions that can impair ECG recording quality (Parkinson's disease, essential tremor)\n* Mental illness\n* Patients with a pacemaker installed\n* Patients with prosthetic valves",{"count":343,"type":20},1200,"It is a prospective, controlled, single-center, observational, non-randomized study. The study is planned to include at least 1000 patients over 18 years old in the training sample and 200 patients over 18 years old in the test sample (the total number of patients is at least 1200 people).\n\nAll patients will undergo an echocardiography examination with a comprehensive analysis of the function of the valves and other structures of the heart according to current recommendations by two independent experts.\n\nRegistration of electrocardiogram will be performed immediately after echocardiography using a single lead ECG monitor (in I standard lead) for 1 minutes.\n\nThe obtained data will be stored in the remote monitoring center of Sechenov University without being linked to the personal data of patients.\n\nA spectral analysis of the electrocardiogram will be performed using a continuous wavelet transform.\n\nThe result of this study will be the identification of ECG parameters that will correlate with valvular heart disease.",[346,347],"Valvular Heart Disease Stenosis and Regurgitation","Valvular Heart Disease",[349,96,97,98],"valvular heart disease","2025-07-25",{"date":352,"type":38},"2025-08-01",{"date":354,"type":38},"2025-01-01",{"date":278,"type":20},{"name":44,"class":45},{"id":358,"slug":359,"hasResults":11,"nctId":360,"briefTitle":361,"officialTitle":362,"acronym":363,"eligibilityCriteria":364,"healthyVolunteers":11,"sex":16,"minAge":365,"maxAge":4,"enrollmentInfo":366,"targetDuration":4,"studyType":56,"phases":4,"briefSummary":368,"conditions":369,"keywords":371,"overallStatus":70,"whyStopped":4,"lastUpdateSubmitDate":376,"lastUpdatePostDateStruct":377,"startDateStruct":379,"completionDateStruct":380,"leadSponsor":382,"locationsCount":79},"100587640","staging-heart-failure-with-preserved-ejection-fraction-100587640","NCT06931015","Staging Heart Failure With Preserved Ejection Fraction","Staging Heart Failure With Preserved Ejection Fraction by Assessing Cardiac Chamber Involvement With Echocardiography","StageHFpEF","Inclusion Criteria:\n\n1. ≥ 40 years of age, male and female\n2. Heart failure symptoms, New York Heart Association (NYHA) II- III\n3. Left ventricular ejection fraction (LVEF) \\> 50% documented by echocardiography at screening\n4. One of the following scenarios:\n\n   A) At screening, N-terminal pro-B-type natriuretic peptide (NT-proBNP) ≥300 pg\u002FmL (sinus rhythm) or ≥600 pg\u002FmL (if AF) and echocardiographic criteria see #5\n\n   B) Previously confirmed HFpEF in combination with a history of hospitalization for HFpEF decompensation \\>30 days before screening defined as the presence of dyspnea and 2 of the following:\n   * Rales on chest auscultation or sings of congestion on X-ray\u002FCT scan\n   * Peripheral Oedema\n   * Elevated NT-proBNP ≥300 pg\u002FmL (sinus rhythm) or ≥600 pg\u002FmL (if AF)\n5. Structural and\u002For functional abnormalities of heart, at least one of the following:\n\n   * Left atrial volume index (LAVI) \\>34 mL\u002Fm2 (if AF \\>40 mL\u002Fm2)\n   * Left ventricular mass index (LVMI) =115 g\u002Fm2 for males and =95 g\u002Fm2 for females\n   * Relative wall thickness \\> 0.42\n   * E\u002Fe' ratio at rest \\>9\n6. Stable doses of oral loop diuretics, if prescribed\n7. Ability to provide informed consent\n\nExclusion Criteria:\n\n* Any prior measurements of LVEF \\\u003C50%\n* Established diagnosis of infiltrative (amyloidosis etc.), hypertrophic cardiomyopathy, muscular dystrophies, complex congenital heart disease, active myocarditis or pericardial constriction\n* Planned interventions, including major cardiac surgery, percutaneous coronary intervention (PCI), transcatheter aortic valve implantation (TAVI), or implantation of cardiac resynchronization therapy\n* Elective PCI or atrial fibrillation ablation within 30 days before visit\n* Moderate and severe valve stenosis and more than mild primary valve regurgitation\n* Acute myocardial infarction in the last 3 months, cardiac surgery, pulmonary embolism or cerebrovascular accident within the last six months\n* Candidates for heart transplantation\n* Secondary hypertension\n* Primary pulmonary hypertension, chronic pulmonary embolism, severe pulmonary disease\n* Any active cancer\n* Infective endocarditis\n* Alcoholic cirrhosis\n* End-stage kidney disease\n* Any other condition judged by the investigator that could account for heart failure symptoms and signs (e.g., anaemia, hypothyroidism).","40 Years",{"count":367,"type":20},700,"Heart failure with preserved ejection fraction (HFpEF) is considered a systemic condition in which the prevalence of cardiovascular, metabolic, pulmonary and renal conditions determine the extent of cardiac involvement. Numerous attempts have been made to phenotype HFpEF, but patients still lack a clinically and\u002For prognostically relevant approach.\n\nProgressive cardiac deterioration in HFpEF appears to be associated with a worse prognosis. However, no attempt has been made to classify the extent of cardiac involvement in HFpEF. Investigators proposed the concept of HFpEF staging according to the extent of cardiac involvement identified by transthoracic echocardiography: Stage 1: isolated left ventricular involvement; Stage 2: left atrial myopathy; Stage 3: pulmonary vasculature involvement; and Stage 4: right chambers involvement.\n\nThe study aims to investigate the associations between the proposed stages and clinical outcomes in HFpEF patients.",[370,127,121],"Heart Failure With Preserved Ejection Fraction",[372,373,374,375],"HFpEF","Staging","Classification","Echocardiography","2025-04-16",{"date":378,"type":38},"2025-04-20",{"date":378,"type":20},{"date":381,"type":20},"2028-12-13",{"name":44,"class":45},{"id":384,"slug":385,"hasResults":11,"nctId":386,"briefTitle":387,"officialTitle":388,"acronym":4,"eligibilityCriteria":389,"healthyVolunteers":11,"sex":179,"minAge":17,"maxAge":390,"enrollmentInfo":391,"targetDuration":4,"studyType":21,"phases":392,"briefSummary":394,"conditions":395,"keywords":397,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":401,"lastUpdatePostDateStruct":402,"startDateStruct":404,"completionDateStruct":406,"leadSponsor":408,"locationsCount":409},"100551319","phase-4-optimization-of-bacterial-vaginosis-treatment-in-women-of-reproductive-age-100551319","NCT06458543","Optimization of Bacterial Vaginosis Treatment in Women of Reproductive Age","Efficacy of Bovhyaluronidase Azoximer on Biofilms Destruction in the Urogenital Tract of the Patients With Reccurent Bacterial Vaginosis.","Inclusion Criteria:\n\n* The written informed consent of the patient to participate in the study;\n* Age (18 - 45 years old);\n* The established diagnosis of Bacterial vaginosis;\n* Absence of pregnancy and lactation.\n\nExclusion Criteria:\n\n* Refusal of the patient from further participation in the study;\n* Lack of patient adherence to treatment;\n* The occurrence of conditions and diseases related to the list of contraindications to the use of the studied drug during the study.\n* The presence of Neisseria gonorrhoeae, Trichomonas vaginalis, confirmed by laboratory;\n* The presence of contraindications to the use of the studied drug according to the instructions for the drug.","45 Years",{"count":290,"type":20},[393],"PHASE4","The purpose of this clinical trial is to study the efficacy of bovgialuronidase azoximere in the treatment and duration of recurrence-free course of bacterial vaginosis in women of reproductive age. The main questions it aims to answer are:\n\n* Is bovgialuronidase azoximer able to destroy G. vaginalis associated biofilms of the vaginal epithelium\n* use of bovgialuronidase azoximer together with Metronidazole increases the effectiveness of treatment of bacterial vaginosis.\n* use of azoximers bovgialuronidase together with Metronidazole increases the duration of relapse-free course of bacterial vaginosis.\n\nParticipants in the experimental and control group will be:\n\n* Amsel criteria assessment\n* Colpotest-PH (vaginal acidity)\n* aminotest with 10% KOH solution (\"fish odor\")\n* microscopic examination of vaginal discharge\n* Bacteriologic culture of vaginal discharge\n* Polymerase chain reaction of epithelial cell scrapings from the vagina\n* electron microscopy of vaginal epithelial cell scrapings\n\nParticipants in the main group will be given the drug Bovgialuronidase azoximer and Metronidazole.\n\nParticipants in the control group: Metronidazole.\n\nResearchers will compare the experimental and control groups to see if there are differences after treatment in biofilm structure, treatment efficacy, and duration of recurrence-free survival.",[396],"Bacterial Vaginosis",[396,398,399,400],"biofilms","bovhyaluronidase azoximer","treatment","2025-04-07",{"date":403,"type":38},"2025-04-09",{"date":405,"type":38},"2024-06-01",{"date":407,"type":20},"2026-06-01",{"name":44,"class":45},2,{"id":411,"slug":412,"hasResults":11,"nctId":413,"briefTitle":414,"officialTitle":415,"acronym":416,"eligibilityCriteria":417,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":418,"enrollmentInfo":419,"targetDuration":4,"studyType":21,"phases":421,"briefSummary":422,"conditions":423,"keywords":426,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":432,"lastUpdatePostDateStruct":433,"startDateStruct":435,"completionDateStruct":437,"leadSponsor":438,"locationsCount":79},"100566200","rifaximin-and-cardiac-function-in-patients-with-heart-failure-with-preserved-ejection-fraction-100566200","NCT06652087","Rifaximin and Cardiac Function in Patients with Heart Failure with Preserved Ejection Fraction","The Effect of Correction of Bacterial Overgrowth Syndrome in the Small Intestine on Cardiac Function in Patients with Heart Failure with Preserved Ejection Fraction","SIBO-HFpEF","Inclusion Criteria:\n\n1. availability of written informed consent of the patient to participate in the study\n2. adult aged ≥18≤80 years' old\n3. body mass index ≥25 kg\u002Fm2\n4. diagnosed with HFpEF: 1) symptoms and\u002For signs of heart failure; 2) left ventricular ejection fraction ≥50%; 3) increased levels of natriuretic peptides (NTproBNP≥125 pg\u002FmL); 4) at least one additional criterion: relevant structural heart disease (hypertrophy of the left ventricle (LVH) and\u002For enlargement of the left atrium (LAE) or diastolic dysfunction\n\nExclusion Criteria:\n\n1. refusal of the patient from further participation in the study\n2. identification of any disease or condition specified in the criteria for non-inclusion and the development of a severe pathological condition in which patient monitoring becomes poorly implemented and the presence of which may make it difficult to interpret the data (gastrointestinal bleeding, myocardial infarction, etc.)","80 Years",{"count":420,"type":20},40,[23],"Single-center, double-blind, randomized, controlled intervention study of the effect of correction of bacterial overgrowth syndrome in the small intestine (SIBO) on cardiac function in patients with heart failure with preserved ejection fraction (HFpEF) (SIBO-HFpEF). The aim of the study is to evaluate the efficacy and safety of rifaximin in patients with HFpEF and SIBO.",[424,425],"Bacterial Overgrowth Syndrome Small Bowel","Heart Failure with Preserved Ejection Fraction",[427,428,429,325,430,431],"Chronic heart failure with preserved ejection fraction","Diastolic dysfunction","Overweight","The gut-heart axis","Small intestinal bacterial overgrowth syndrome","2024-10-21",{"date":434,"type":38},"2024-10-22",{"date":436,"type":38},"2024-09-02",{"date":250,"type":20},{"name":44,"class":45},{"id":440,"slug":441,"hasResults":11,"nctId":442,"briefTitle":443,"officialTitle":443,"acronym":444,"eligibilityCriteria":445,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":446,"targetDuration":4,"studyType":21,"phases":447,"briefSummary":448,"conditions":449,"keywords":452,"overallStatus":70,"whyStopped":4,"lastUpdateSubmitDate":460,"lastUpdatePostDateStruct":461,"startDateStruct":463,"completionDateStruct":464,"leadSponsor":466,"locationsCount":79},"100565604","remote-multichannel-monitoring-of-patients-with-chronic-diseases-using-speech-technologies-based-on-artificial-intelligence-100565604","NCT06644339","Remote Multichannel Monitoring of Patients With Chronic DIseAses Using Speech technoLogies Based On Artificial intelliGence","DIALOG","Inclusion Criteria:\n\n* Disease diagnosed according to the latest Clinical practice guidelines\n* Stable condition at the time of discharge from the hospital\n* Written informed consent to participate in the study\n\nNon-inclusion criteria:\n\n* Diagnosed dementia or severe cognitive impairment\n* The inability to use automatic devices to register blood pressure at home, a blood glucose meter\n* Alcohol or drug abuse\n* Inability to contact a voice assistant and other study requirements, due to major co-morbidities, social or financial issues, or a history of noncompliance with medical regimens, that might compromise the patient's ability to understand and\u002For comply with the protocol instructions or follow-up procedures\n\nExclusion Criteria:\n\n* Unwillingness of the patient to continue participating in the study\n* The development of conditions related to the criteria of non-inclusion",{"count":89,"type":20},[23],"DIALOG is a study to assess the efficacy and safety of remote patient monitoring using virtual operator voice technologies and a business intelligence (BI) system for timely detection, prevention of early complications, worsening of the condition, and other adverse events in patients who have been discharged from the hospital.",[121,152,149,450,451],"Lymphoproliferative Disease","Total Knee Replacement",[453,159,163,454,455,456,457,458,459],"heart failure","lymphoproliferative diseases","knee replacement","remote monitoring","mHealth","telemedicine","voice assistant","2024-10-15",{"date":462,"type":38},"2024-10-16",{"date":460,"type":20},{"date":465,"type":20},"2025-04-30",{"name":44,"class":45},{"id":468,"slug":469,"hasResults":11,"nctId":470,"briefTitle":471,"officialTitle":472,"acronym":4,"eligibilityCriteria":473,"healthyVolunteers":11,"sex":474,"minAge":475,"maxAge":476,"enrollmentInfo":477,"targetDuration":4,"studyType":56,"phases":4,"briefSummary":478,"conditions":479,"keywords":482,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":486,"lastUpdatePostDateStruct":487,"startDateStruct":489,"completionDateStruct":491,"leadSponsor":493,"locationsCount":79},"100373717","active-surveillance-for-low-risk-prostate-cancer-100373717","NCT04146077","Active Surveillance for Low Risk Prostate Cancer","Active Surveillance Methodology for Low Risk Prostate Cancer","Inclusion Criteria:\n\n* prostate adenocarcinoma verified by at least 12 core biopsy\n* patient must understand the sense of research, agree to participate and sign a form of agreement\n* low oncological risk according to EAU (European Association of Urology) Guidelines: stage T1-T2a, PSA\\\u003C10 ng\u002Fml, ISUP (International Society of Urological Pathologists score)=1 (Gleason score 3+3=6)\n* not more than 33% cores with adenocarcinoma\n\nExclusion Criteria:\n\n* previous treatment of prostate cancer\n* other prostatic malignant neoplasms\n* other oncological diseases\n* treatment with 5-alfa-reductase inhibitors\n* patient's refuse to continue study\n* patient's desire to begin treatment","MALE","50 Years","75 Years",{"count":290,"type":20},"An active surveillance protocol for patients diagnosed low-risk prostate cancer will be held. We plan to use PSA (prostate-specific antigen) testing, DRE (digital rectal examination), TRUS (transrectal ultrasound), MRI (magnetic resonance imaging) and follow-up biopsies to monitor patients and detect cancer progression in time.",[480,481],"Prostate Cancer","Prostate Adenocarcinoma",[483,484,485],"prostate cancer","active surveillance","low oncological risk","2021-07-21",{"date":488,"type":38},"2021-07-22",{"date":490,"type":38},"2019-10-01",{"date":492,"type":20},"2026-10",{"name":44,"class":45},""]